Half-Year 2022 Financial and Clinical Trials Update
Diagnostics Division quarterly sales and CER growth¹
Reported
Restatement³
Roche
Q121
Q2 21
Q3 21
Q2 22
CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER
Q4 21
Q122
Q121
Q2 21
Q3 21
Q122 Q2 22
CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER CHFm %CER
Q4 21
Core Lab 2,3
Point of Care³
Molecular Lab³
Diabetes Care
Pathology Lab
Diagnostics Div. 4,330
1,765 31
716 281
1,107 86
1,961 36
900 424
1,884 12
442 143
525
1,863 10
-2
1,873 8 1,961 1
1,786 31 1,984 36
1,907 12 1,883 9 1,896 8
1,979 1
1,302
84
987 10
806 255
992 464
617 222
719
1,109
19 1,238 21
1,358 15
1,376
26
965 -13
996 87
994 9
1,040 5
15
1,144 7
1,466 84 1,143 15
1,189 21
791 -20
460 13
434
7
400 -7
396
-2
417
-7
415
-3
460 13
434 7
400 -7
396 -2
417 -7
415 -3
282 9
308
32
32
299 4
313
7
318 14
334
7
282 9
308 32
299
+
313 7
318 14
334
7
55 4,712
48
4,263
18
4,455
8
5,286
24
24
4,662
0
4,330
55
4,712 48
4,263
18 4,455
8
5,286
24
4,662
0
CER-Constant Exchange Rates; ' versus same period of prior year; 2 incl. Roche Information Solutions; 3 Sales in the Point of Care customer area include sales from the Liat business (POC molecular), and sales in the Core
Lab customer area include sales from the Life Science Alliances, both previously shown as part of Molecular Lab customer area. The comparative information for 2021 has been updated accordingly. In Q1 21 POC
molecular sales = 90mCHF, Q2 21=92mCHF, Q3 21=175mCHF, Q4 21-194mCHF. In Q1 21 LS Alliances = 21mCHF, Q2 21-23mCHF, Q3 21-23m CHF, Q4 21=20mCHF.
188View entire presentation